CIO Bulletin

Cleerly is a digital healthcare company creating a world without heart attacks

Cleerly goes beyond traditional measures of heart disease by performing a comprehensive assessment of each coronary artery and branch.

Cleerly’s AI-enabled evaluation of Coronary CT Angiography identifies, characterizes, and quantifies plaque buildup to support physicians in determining a patient's risk of a heart attack and developing a treatment plan to improve heart health.

Precision health

Cleerly’s technology quantifies and characterizes coronary artery disease (CAD) to help tailor therapies to a patient’s actual disease instead of indirect measures, such as surrogates, symptoms and sequela of disease as has been done historically.

Built for physicians and patients

Cleerly’s offerings also include innovative digital and print tools that transform complex imaging data into actionable clinical insights for clinicians and their patients.

Cleerly’s approach

A new paradigm: For over 50 years, cardiology has really been “sickcare,” with a focus on symptoms of heart disease rather than the disease itself, atherosclerosis. Over 10 years of clinical trial data have revealed that it's the type of atherosclerotic plaque buildup that matters most. Instead of waiting for reduced blood flow or blockages, it's time to get ahead of the problem, evaluate the underlying disease, and treat it with precision.

Cleerly's analysis delivers a comprehensive assessment of each of your coronary arteries and branches. Cleerly identifies, characterizes, and quantifies plaques with precision to support your physician in determining your risk of heart attack and guiding your treatment plan to maintain heart health.

Cleerly for providers

Sudden coronary death due to fatal heart attacks has remained the #1 cause of mortality and morbidity in the world for the last 50 years, with an individual dying from cardiovascular disease every 1.7 seconds.

In the past, Cleerly has focused on surrogates of disease (like cholesterol), symptoms of disease (like chest pain or shortness of breath), or sequela of disease (like ischemia or stenosis). Yet the majority of coronary lesions that cause heart attack are unpredictably related to surrogates, are silent, and do not cause ischemia or stenosis. It’s time to measure actual disease, not indirect markers of disease.

Phenotyping: it's the characterization of disease that matters most

Cleerly technology characterizes and quantifies atherosclerotic plaque in the arteries, letting you know not only how much is there but what type of plaque is present. Plaque type has been shown to be the strongest discriminant of future heart attack risk, and perhaps the greatest indicator of your patient's likelihood of an impending cardiac event.

Stabilizing high-risk plaques has been achieved with lifestyle changes and medical therapy through the transformation of non-calcified fatty plaques to calcified stable plaques.

Transformation of non-calcified high-risk plaques to calcified low-risk plaques has been shown to be associated with reduced rates of major adverse cardiovascular events.

Transformative digital care

Cleerly offers a transformative digital care pathway for evaluation and management of Coronary Artery Disease (CAD). Leveraging latest-generation artificial intelligence (AI) frameworks, Cleerly’s solutions perform comprehensive and quantitative assessment of CAD, with clinical solutions delivered to imaging physicians, clinicians and patients.

A New Standard of Care: Shifting care paradigm from symptom-driven to risk-based.

Transforming Images Into Intelligence: End-to-end AI-based approach to translate imaging science into actionable clinical insights.

Innovative Patient-Specific Education: Improved technologies to allow a patient to visualize their own disease in order to optimize shared decision making and adherence to therapy.

Phenotype-Driven Personalized Medicine: Only method to tailor therapy to an individual’s actual disease characteristics.

Direct Non-invasive Disease Tracking: Only method to directly quantify disease progression or stabilization over time, and guide changes in medical therapy.

James K. Min, MD

James K. Min, MD is a former Professor of Radiology and Medicine at Weill Cornell Medical College and the Director of the Dalio Institute of Cardiovascular Imaging (ICI) at NewYork-Presbyterian. He is a board-certified cardiologist with a clinical focus on cardiovascular disease prevention and cardiovascular imaging.

With a clinical and research focus on coronary artery disease, Min has published more than 500 peer-reviewed manuscripts that have been funded, in part, by numerous grants awarded by the National Institutes of Health and the Dalio Foundation. Min has served as Principal Investigator on numerous landmark multicenter clinical trials and registries, including the ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC and PARADIGM trials. Min is also the director of a state-of-the-art core laboratory for coronary computed tomography for several multicenter clinical trials, including for the PACIFIC and ISCHEMIA trials.

For Min, the development, validation and dissemination of Cleerly’s products and services offer him an opportunity to translate the large-scale clinical trial research he has spent doing in the last 17 years into daily clinical practice through innovative solutions in coronary heart disease that have not existed in the marketplace to date.

Min received his BA from the University of Chicago, and his medical degree from Temple University Medical School. He completed his internship, residency and cardiovascular medicine fellowship at the University of Chicago Hospitals.